New combo aims to revive failed cancer immunotherapy
NCT ID NCT07404332
First seen Feb 16, 2026 · Last updated May 22, 2026 · Updated 13 times
Summary
This early-phase study tests whether adding the drug 5-Azacitidine to standard immunotherapy can help patients whose solid tumors no longer respond to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic tumors will receive the combination to find the safest dose and check for tumor shrinkage. The goal is to overcome treatment resistance without offering a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Iowa Health Care
Iowa City, Iowa, 52242, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.